Zimbabwe has rejected a significant American healthcare agreement valued at $367m (£272m) over five years over Washington's demand for sensitive biological samples.
This move was revealed following a government memo from December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
An official representative later stated that the US was requesting genetic material for scientific study and commercial purposes but refused to guarantee the benefits from any future treatments.
"We must now begin the challenging and unfortunate task of ending our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged further negotiations to reach a agreement suitable to all parties so the country's critical HIV programme can be sustained.
Broader Context
Zimbabwe's decision follows a comparable case in Kenya, where a high court blocked a related deal with the US after legal challenges were raised about the safety of citizens' medical information.
After returning to office last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government agreements to enhance openness and accountability.
As per statements, 16 African countries have to date signed these new agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving HIV treatment through American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, with no corresponding assurance of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," his statement read.
"Put simply, our country would supply the raw materials for medical research without any assurance that the final treatments would be accessible to our citizens if a new health crisis emerge."
National Interest and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral health agreements were upending systems previously established via the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing framework designed to manage potential global health emergencies.
"This framework is designed to guarantee that when a country provides its data, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
The government's concerns over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to continued discussions with our US partners on how future collaboration might be structured in a manner that honours the sovereignty and interests of both nations."
Health Experts Response
A leading public health body stated it acknowledged the government's concerns, but urged that talks need to persist given that a large portion of the nation's Aids initiatives were funded by international support.
"Where specific concerns exist, such as those involving information security or agreement terms, these can frequently be resolved through technical clarification and mutually agreed protections," it commented.
The situation highlights the complex challenges between receiving vital foreign assistance and protecting national sovereignty in an ever more data-driven world.